Kidney Cancer Coverage from Every Angle

Toni Choueiri, MD, on Newer Agents in the Treatment of Renal Cell Carcinoma

Posted: Tuesday, July 11, 2017

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses study findings on four novel agents—axitinib, avelumab, pazopanib, and pembrolizumab—in the treatment of renal cell carcinoma.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.